Vaccine Platform	Representative Vaccine	Antigen	Safety Profile	Phase	Advantages	Limitations	Ref.
Inactivated Vaccine	ZPIV	Whole virus	No vaccine-related adverse events of special interest were reported in any subjects	Phase I	Mature manufacturing technology, favorable safety profile, and excellent storage stability	Adjuvant-dependent immunogenicity; requires multiple doses; high production cost	[186]
Live Attenuated Vaccine	rZIKV /D4Δ30-713	rZIKV /D4Δ30–713	Safe and well-tolerated in healthy adults	Phase I	Induces durable immune response without adjuvants or multiple doses	Risk of insufficient immune stimulation due to over-attenuation; potential safety risks; contraindicated in immunocompromised populations and pregnant individuals	[187]
mRNA Vaccine	mRNA-1893	prM-E	Most vaccine-related adverse events were grade 1 or 2, with an overall favorable tolerability profile	Phase II	Short R&D cycle; no risk of host genome integration; favorable safety profile	Poor thermal stability; strict cold chain requirement; need for booster immunization	[188]
DNA Vaccine	VRC5283	prM-E	Favorable safety profile with no serious adverse events reported; incidence of local reactions <10%	Phase II	High chemical stability; low production cost	Weaker immunogenicity compared to mRNA and inactivated vaccines; susceptibility to degradation by endogenous nucleases in vivo	[189]
Viral Vector Vaccine	MV-ZIKA-RSP	prM/E	Favorable safety profile; pre-existing anti-vector immunity may reduce vaccine immunogenicity	Phase I	Induces comprehensive humoral and cellular immune responses; controllable production cost	Contraindicated in immunocompromised populations and pregnant individuals	[190]
Virus-Like Particle (VLP) Vaccine	EDIII -QβVLP	EDIII	No risk of viral infection and replication; negligible ADE risk	Preclinical	Viral genome-free; excellent safety profile; accurate display of conformational epitopes	High production cost; difficulty in large-scale manufacturing; slow clinical translation progress	[129]
Recombinant Subunit Vaccine	E80	E	Low-level ADE in vitro; no infection enhancement in vivo	Preclinical	Superior safety profile; controllable production cost	Low intrinsic immunogenicity; requires potent adjuvants; need for multiple doses	[191]